Immuneering Corporation Depreciation
Immuneering Corporation (IMRX) reported Depreciation of $355.81 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2025-03-20
- Immuneering Corporation depreciation for the quarter ending 2024-12-31 was $86.12K, a 4.05% decline year-over-year.
- Immuneering Corporation depreciation for the quarter ending 2024-09-30 was $88.95K, a 13.61% increase year-over-year.
- Immuneering Corporation depreciation for the quarter ending 2024-06-30 was $90.53K, a 15.71% increase year-over-year.
- Immuneering Corporation depreciation for the quarter ending 2024-03-31 was $90.21K, a 17.88% increase year-over-year.
- Immuneering Corporation depreciation for fiscal 2024 was $355.81K, a 10.22% increase from fiscal 2023.
- Immuneering Corporation depreciation for fiscal 2023 was $322.82K, a 30.59% increase from fiscal 2022.
- Immuneering Corporation depreciation for fiscal 2022 was $247.20K, a 443.69% increase from fiscal 2021.
- Immuneering Corporation depreciation for fiscal 2021 was $45.47K, a 86.89% increase from fiscal 2020.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2024-12-31 | $86.12K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $175.06K derived: sum of 2 quarters · filed 2025-03-20 | $265.60K derived: sum of 3 quarters · filed 2025-03-20 | $355.81K 10-K · filed 2025-03-20 |
| 2024-09-30 | $88.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $179.48K derived: sum of 2 quarters · filed 2024-11-13 | $269.69K 10-Q · filed 2024-11-13 | $359.44K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-06-30 | $90.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $180.74K 10-Q · filed 2024-08-06 | $270.50K derived: sum of 3 quarters · filed 2025-03-20 | $348.79K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-03-31 | $90.21K 10-Q · filed 2024-05-07 | $179.96K derived: sum of 2 quarters · filed 2025-03-20 | $258.26K derived: sum of 3 quarters · filed 2025-03-20 | $336.50K derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-12-31 | $89.75K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $168.05K derived: sum of 2 quarters · filed 2025-03-20 | $246.29K derived: sum of 3 quarters · filed 2025-03-20 | $322.82K 10-K · filed 2025-03-20 |
| 2023-09-30 | $78.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $156.53K derived: sum of 2 quarters · filed 2024-11-13 | $233.06K 10-Q · filed 2024-11-13 | $309.92K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $78.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $154.77K 10-Q · filed 2024-08-06 | $231.63K derived: sum of 3 quarters · filed 2024-08-06 | $299.70K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $76.53K 10-Q · filed 2024-05-07 | $153.39K derived: sum of 2 quarters · filed 2024-05-07 | $221.46K derived: sum of 3 quarters · filed 2024-05-07 | $276.02K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $76.86K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $144.94K derived: sum of 2 quarters · filed 2024-03-01 | $199.50K derived: sum of 3 quarters · filed 2024-03-01 | $247.20K 10-K · filed 2024-03-01 |
| 2022-09-30 | $68.08K 10-Q · filed 2022-11-10 | $122.64K derived: sum of 2 quarters · filed 2022-11-10 | $170.34K 10-Q · filed 2023-11-09 | $185.15K derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-06-30 | $54.56K 10-Q · filed 2022-08-10 | $102.26K 10-Q · filed 2023-08-03 | $117.08K derived: sum of 3 quarters · filed 2023-05-04 | $129.06K derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | $47.70K 10-Q · filed 2023-05-04 | $62.52K derived: sum of 2 quarters · filed 2023-05-04 | $74.50K derived: sum of 3 quarters · filed 2023-05-04 | $84.30K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $14.81K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $26.79K derived: sum of 2 quarters · filed 2023-03-06 | $36.60K derived: sum of 3 quarters · filed 2023-03-06 | $45.47K 10-K · filed 2023-03-06 |
| 2021-09-30 | $11.98K 10-Q · filed 2022-11-10 | $21.79K derived: sum of 2 quarters · filed 2022-11-10 | $30.65K 10-Q · filed 2022-11-10 | $38.10K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $9.81K 10-Q · filed 2022-08-10 | $18.67K 10-Q · filed 2022-08-10 | $26.12K derived: sum of 3 quarters · filed 2022-08-10 | $31.78K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $8.87K 10-Q · filed 2022-05-10 | $16.32K derived: sum of 2 quarters · filed 2022-05-10 | $21.97K derived: sum of 3 quarters · filed 2022-05-10 | $27.89K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $7.45K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $13.11K derived: sum of 2 quarters · filed 2022-03-10 | $19.02K derived: sum of 3 quarters · filed 2022-03-10 | $24.33K 10-K · filed 2022-03-10 |
| 2020-09-30 | $5.66K 10-Q · filed 2021-11-09 | $11.57K derived: sum of 2 quarters · filed 2021-11-09 | $16.88K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $5.92K 10-Q · filed 2021-09-09 | $11.22K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |